Antibody-mediated kidney allograft rejection: Therapeutic options and their experimental rationale

Transplant International

Volumn 25, Issue 6, 2012, Pages 623-632

  Fehr, Thomas ^a   Gaspert, Ariana ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

antibody mediated rejection; bortezomib; eculizumab; immunoadsorption; intravenous immunoglobulin; rituximab

Indexed keywords

BORTEZOMIB; CD20 ANTIGEN; ECULIZUMAB; IMMUNOGLOBULIN; RITUXIMAB; THYMOCYTE ANTIBODY;

ANTIBODY MEDIATED KIDNEY ALLOGRAFT REJECTION; AUTOIMMUNE DISEASE; CONFERENCE PAPER; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INFECTION RISK; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PLASMAPHERESIS; POLYPHARMACY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SPLENECTOMY;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BORONIC ACIDS; CHRONIC DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSORBENT TECHNIQUES; ISOANTIBODIES; KIDNEY TRANSPLANTATION; PLASMA EXCHANGE; PYRAZINES; SPLENECTOMY;

EID: 84861192175     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01453.x     Document Type: Conference Paper

References (58)

1. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB,. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580.
2. Srinivas TR, Meier-Kriesche HU,. Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clin J Am Soc Nephrol 2008; 3 (Suppl. 2): S101.
3. Safinia N, Afzali B, Atalar K, Lombardi G, Lechler RI,. T-cell alloimmunity and chronic allograft dysfunction. Kidney Int Suppl 2010; 78: S2.
4. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7: 864.
5. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
6. Riethmuller S, Ferrari-Lacraz S, Muller MK, et al. Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation 2010; 90: 160.
7. Soulillou JP, Guyot C, Guimbretiere J, et al. Plasma exchange in early kidney graft rejection associated with anti-donor antibodies. Nephron 1983; 35: 158.
8. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887.
9. Pascual M, Saidman S, Tolkoff-Rubin N, et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1998; 66: 1460.
10. Bohmig GA, Wahrmann M, Regele H, et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant 2007; 7: 117.
11. Schmaldienst S, Mullner M, Goldammer A, et al. Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases? Rheumatology (Oxford) 2001; 40: 513.
12. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
13. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318.
14. Muta T, Kurosaki T, Misulovin Z, Sanchez M, Nussenzweig MC, Ravetch JV,. A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling. Nature 1994; 368: 70.
15. Kaneko Y, Nimmerjahn F, Ravetch JV,. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313: 670.
16. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV,. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320: 373.
17. Seite JF, Cornec D, Renaudineau Y, Youinou P, Mageed RA, Hillion S,. IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. Blood 2010; 116: 1698.
18. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV,. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 2011; 475: 110.
19. Spycher M, Matozan K, Minnig K, et al. In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations. Vox Sang 2009; 97: 348.
20. Watanabe J, Scornik JC,. IVIG and HLA antibodies. Evidence for inhibition of complement activation but not for anti-idiotypic activity. Am J Transplant 2005; 5: 2786.
21. Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66: 800.
22. Casadei DH, del CR, Opelz G, et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001; 71: 53.
23. Shehata N, Palda VA, Meyer RM, et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. Transfus Med Rev 2010; 24 (Suppl. 1): S7.
24. Venetz JP, Pascual M,. New treatments for acute humoral rejection of kidney allografts. Expert Opin Investig Drugs 2007; 16: 625.
25. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl. 3): S1.
26. Loken MR, Shah VO, Dattilio KL, Civin CI,. Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. Blood 1987; 70: 1316.
27. Genberg H, Kumlien G, Wennberg L, Berg U, Tyden G,. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 2008; 85: 1745.
28. Wu GD, He Y, Chai NN, et al. Anti-CD20 antibody suppresses anti-HLA antibody formation in a HLA-A2 transgenic mouse model of sensitization. Transpl Immunol 2008; 19: 178.
29. Faguer S, Kamar N, Guilbeaud-Frugier C, et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007; 83: 1277.
30. Mulley WR, Hudson FJ, Tait BD, et al. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation 2009; 87: 286.
31. Kamar N, Milioto O, Puissant-Lubrano B, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2010; 10: 89.
32. Gea-Banacloche JC,. Rituximab-associated infections. Semin Hematol 2010; 47: 187.
33. Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 1099.
34. Everly MJ, Rebellato LM, Ozawa M, et al. Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection. Transplantation 2010; 89: 962.
35. Kaposztas Z, Podder H, Mauiyyedi S, et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009; 23: 63.
36. Waiser J, Budde K, Schutz M, et al. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol Dial Transplant 2011; in press.
37. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201.
38. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754.
39. Flechner SM, Fatica R, Askar M, et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010; 90: 1486.
40. Rother RP, Arp J, Jiang J, et al. C5 blockade with conventional immunosuppression induces long-term graft survival in presensitized recipients. Am J Transplant 2008; 8: 1129.
41. Tillou X, Poirier N, Le Bas-Bernardet S, et al. Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int 2010; 78: 152.
42. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9: 231.
43. Lonze BE, Dagher NN, Simpkins CE, et al. Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access. Am J Transplant 2010; 10: 2154.
44. Biglarnia AR, Nilsson B, Nilsson T, et al. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transpl Int 2011; 24: e61.
45. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405.
46. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363: 513.
47. Fontaine MJ, Kuo J, Chen G, et al. Complement (C1q) fixing solid-phase screening for HLA antibodies increases the availability of compatible platelet components for refractory patients. Transfusion 2011; 51: 2611.
48. Locke JE, Zachary AA, Haas M, et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007; 7: 842.
49. Kaplan B, Gangemi A, Thielke J, Oberholzer J, Sankary H, Benedetti E,. Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation 2007; 83: 99.
50. Roberti I, Geffner S, Vyas S,. Successful rescue of refractory acute antibody-mediated renal allograft rejection with splenectomy-a case report. Pediatr Transplant 2011; 16: E49.
51. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518.
52. Loupy A, Suberbielle-Boissel C, Zuber J, et al. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation 2010; 89: 1403.
53. Billing H, Rieger S, Ovens J, et al. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation 2008; 86: 1214.
54. Fehr T, Rusi B, Fischer A, Hopfer H, Wuthrich RP, Gaspert A,. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009; 87: 1837.
55. Schwaiger E, Regele H, Wahrmann M, et al. Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report. Clin Transpl 2010; 391.
56. Lonze BE, Dagher NN, Simpkins CE, et al. The fate of anti-HLA antibody among renal transplantation recipients treated with bortezomib. Clin Transpl 2009; 377.
57. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010; 10: 681.
58. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007; 7: 2124.